Patient characteristics
| Characteristic . | Overall (N = 259)∗ . | No weight loss (n = 191 [74%])∗ . | Weight loss (n = 68 [26%])∗ . | P value† . |
|---|---|---|---|---|
| Diagnosis | .5 | |||
| Large BCL | 222 (86%) | 162 (85%) | 60 (88%) | |
| Mantle cell lymphoma | 21 (8.1%) | 15 (7.9%) | 6 (8.8%) | |
| Follicular lymphoma | 16 (6.2%) | 14 (7.3%) | 2 (2.9%) | |
| BMI category 3 mo before CAR | .5 | |||
| Obese | 67 (26%) | 54 (28%) | 13 (19%) | |
| Overweight | 82 (32%) | 60 (31%) | 22 (32%) | |
| Normal | 103 (40%) | 72 (38%) | 31 (46%) | |
| Underweight | 7 (2.7%) | 5 (2.6%) | 2 (2.9%) | |
| Age at CAR infusion | .8 | |||
| ≤65 y | 125 (48%) | 93 (49%) | 32 (47%) | |
| >65 y | 134 (52%) | 98 (51%) | 36 (53%) | |
| Sex | .10 | |||
| Male | 166 (64%) | 128 (67%) | 38 (56%) | |
| Female | 93 (36%) | 63 (33%) | 30 (44%) | |
| Race | .3 | |||
| White | 202 (78%) | 146 (76%) | 56 (82%) | |
| Black | 14 (5.4%) | 9 (4.7%) | 5 (7.4%) | |
| Asian | 23 (8.9%) | 18 (9.4%) | 5 (7.4%) | |
| Other | 10 (3.9%) | 10 (5.2%) | 0 | |
| Not reported/unknown | 10 (3.9%) | 8 (4.1%) | 2 (3%) | |
| Ethnicity | .2 | |||
| Hispanic or Latino | 16 (6.2%) | 15 (7.9%) | 1 (1.5%) | |
| Not Hispanic or Latino | 234 (90%) | 170 (89%) | 64 (94%) | |
| Not applicable/unknown | 9 (3.5%) | 6 (3.1%) | 3 (4.4%) | |
| Karnofsky performance status (n = 258) | .005 | |||
| ≥90 | 76 (29%) | 65 (34%) | 11 (16%) | |
| <90 | 182 (71%) | 125 (66%) | 57 (84%) | |
| History of CNS lymphoma (n = 251) | 48 (19%) | 35 (19%) | 13 (19%) | >.9 |
| TMTV‡ (n = 205) | 22 (1-117) | 12 (0-76) | 74 (12-262) | <.001 |
| Stable/progressive disease at time of apheresis (n = 254) | 190 (75%) | 134 (72%) | 56 (84%) | .054 |
| Bridging therapy receipt | 200 (77%) | 138 (72%) | 62 (91%) | .001 |
| Stable/progressive disease at time of CAR | 153 (59%) | 107 (56%) | 46 (68%) | .094 |
| Preapheresis treatment lines (n = 254) | .5 | |||
| ≤3 lines | 162 (64%) | 122 (66%) | 40 (59%) | |
| 4-5 lines | 53 (21%) | 38 (20%) | 15 (22%) | |
| 6+ lines | 39 (15%) | 26 (14%) | 13 (19%) | |
| History of auto-HCT (n = 258) | 46 (18%) | 37 (19%) | 9 (13%) | .2 |
| History of allo-HCT (n = 258) | 10 (3.9%) | 7 (3.7%) | 3 (4.4%) | .7 |
| History of CAR T-cell therapy (n = 239) | 5 (2.1%) | 3 (1.7%) | 2 (3.1%) | .6 |
| CAR T-cell product | .034 | |||
| Axi-cel | 122 (47%) | 82 (43%) | 40 (59%) | |
| Tisa-cel | 58 (22%) | 44 (23%) | 14 (21%) | |
| Liso-cel | 68 (26%) | 58 (30%) | 10 (15%) | |
| Brexu-cel | 11 (4.2%) | 7 (3.7%) | 4 (5.9%) | |
| Lymphodepletion | .2 | |||
| Cyclophosphamide/fludarabine | 228 (88%) | 165 (86%) | 63 (93%) | |
| Bendamustine | 31 (12%) | 26 (14%) | 5 (7.4%) | |
| Days between apheresis and infusion | 37 (31-49) | 37 (31-46) | 40 (32-51) | .4 |
| Characteristic . | Overall (N = 259)∗ . | No weight loss (n = 191 [74%])∗ . | Weight loss (n = 68 [26%])∗ . | P value† . |
|---|---|---|---|---|
| Diagnosis | .5 | |||
| Large BCL | 222 (86%) | 162 (85%) | 60 (88%) | |
| Mantle cell lymphoma | 21 (8.1%) | 15 (7.9%) | 6 (8.8%) | |
| Follicular lymphoma | 16 (6.2%) | 14 (7.3%) | 2 (2.9%) | |
| BMI category 3 mo before CAR | .5 | |||
| Obese | 67 (26%) | 54 (28%) | 13 (19%) | |
| Overweight | 82 (32%) | 60 (31%) | 22 (32%) | |
| Normal | 103 (40%) | 72 (38%) | 31 (46%) | |
| Underweight | 7 (2.7%) | 5 (2.6%) | 2 (2.9%) | |
| Age at CAR infusion | .8 | |||
| ≤65 y | 125 (48%) | 93 (49%) | 32 (47%) | |
| >65 y | 134 (52%) | 98 (51%) | 36 (53%) | |
| Sex | .10 | |||
| Male | 166 (64%) | 128 (67%) | 38 (56%) | |
| Female | 93 (36%) | 63 (33%) | 30 (44%) | |
| Race | .3 | |||
| White | 202 (78%) | 146 (76%) | 56 (82%) | |
| Black | 14 (5.4%) | 9 (4.7%) | 5 (7.4%) | |
| Asian | 23 (8.9%) | 18 (9.4%) | 5 (7.4%) | |
| Other | 10 (3.9%) | 10 (5.2%) | 0 | |
| Not reported/unknown | 10 (3.9%) | 8 (4.1%) | 2 (3%) | |
| Ethnicity | .2 | |||
| Hispanic or Latino | 16 (6.2%) | 15 (7.9%) | 1 (1.5%) | |
| Not Hispanic or Latino | 234 (90%) | 170 (89%) | 64 (94%) | |
| Not applicable/unknown | 9 (3.5%) | 6 (3.1%) | 3 (4.4%) | |
| Karnofsky performance status (n = 258) | .005 | |||
| ≥90 | 76 (29%) | 65 (34%) | 11 (16%) | |
| <90 | 182 (71%) | 125 (66%) | 57 (84%) | |
| History of CNS lymphoma (n = 251) | 48 (19%) | 35 (19%) | 13 (19%) | >.9 |
| TMTV‡ (n = 205) | 22 (1-117) | 12 (0-76) | 74 (12-262) | <.001 |
| Stable/progressive disease at time of apheresis (n = 254) | 190 (75%) | 134 (72%) | 56 (84%) | .054 |
| Bridging therapy receipt | 200 (77%) | 138 (72%) | 62 (91%) | .001 |
| Stable/progressive disease at time of CAR | 153 (59%) | 107 (56%) | 46 (68%) | .094 |
| Preapheresis treatment lines (n = 254) | .5 | |||
| ≤3 lines | 162 (64%) | 122 (66%) | 40 (59%) | |
| 4-5 lines | 53 (21%) | 38 (20%) | 15 (22%) | |
| 6+ lines | 39 (15%) | 26 (14%) | 13 (19%) | |
| History of auto-HCT (n = 258) | 46 (18%) | 37 (19%) | 9 (13%) | .2 |
| History of allo-HCT (n = 258) | 10 (3.9%) | 7 (3.7%) | 3 (4.4%) | .7 |
| History of CAR T-cell therapy (n = 239) | 5 (2.1%) | 3 (1.7%) | 2 (3.1%) | .6 |
| CAR T-cell product | .034 | |||
| Axi-cel | 122 (47%) | 82 (43%) | 40 (59%) | |
| Tisa-cel | 58 (22%) | 44 (23%) | 14 (21%) | |
| Liso-cel | 68 (26%) | 58 (30%) | 10 (15%) | |
| Brexu-cel | 11 (4.2%) | 7 (3.7%) | 4 (5.9%) | |
| Lymphodepletion | .2 | |||
| Cyclophosphamide/fludarabine | 228 (88%) | 165 (86%) | 63 (93%) | |
| Bendamustine | 31 (12%) | 26 (14%) | 5 (7.4%) | |
| Days between apheresis and infusion | 37 (31-49) | 37 (31-46) | 40 (32-51) | .4 |
P-values below 0.05 are bolded.
allo-HCT, allogeneic hematopoietic cell transplant; auto-HCT, autologous hematopoietic cell transplant; CNS, central nervous system; IQR, interquartile range.
n (%); median (IQR).
Fisher exact test; Pearson χ2 test; Wilcoxon rank-sum test.
Last PET scan assessment before LDC time point.